Skeletal muscle involvement

Scleroderma: From Pathogenesis to Comprehensive Management

Volumn , Issue , 2012, Pages 525-530

  Mammen, Andrew L ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Aldolase; Anti PM SCL; Creatine phosphokinase (CPK); Dermatomyositis; Electromyography; Myofiber necrosis; Myopathy; Polymyositis

Indexed keywords

EID: 85026442377     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-5774-0_43     Document Type: Chapter

References (42)

1. Westphal C. Zwei Falle von Scleerodermie. Charite-Annalen (Berlin). 1876;3:341-60.
2. Medsger Jr TA, Rodnan GP, Moossy J, Vester JW. Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). Arthritis Rheum. 1968;11(4):554-68.
3. Thompson JM, Bluestone R, Bywaters EG, Dorling J, Johnson M. Skeletal muscle involvement in systemic sclerosis. Ann Rheum Dis. 1969;28(3):281-8.
4. Clements PJ, Furst DE, Campion DS, et al. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum. 1978;21(1):62-71.
5. West SG, Killian PJ, Lawless OJ. Association of myositis and myocarditis in progressive systemic sclerosis. Arthritis Rheum. 1981;24(5):662-8.
6. Russell ML, Hanna WM. Ultrastructure of muscle microvasculature in progressive systemic sclerosis: relation to clinical weakness. J Rheumatol. 1983;10(5):741-7.
7. Averbuch-Heller L, Steiner I, Abramsky O. Neurologic manifestations of progressive systemic sclerosis. Arch Neurol. 1992;49(12):1292-5.
8. Hietaharju A, Jaaskelainen S, Kalimo H, Hietarinta M. Peripheral neuromuscular manifestations in systemic sclerosis (scleroderma). Muscle Nerve. 1993;16(11):1204-12.
9. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Clinical and laboratory features of scleroderma patients developing skeletal myopathy. Clin Rheumatol. 2005;24(2):99-102.
10. Follansbee WP, Zerbe TR, Medsger Jr TA. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J. 1993;125(1):194-203.
11. Rosato E, Rossi C, Salsano F. Dropped head syndrome and systemic sclerosis. Joint Bone Spine. 2009;76(3):301-3.
12. Garcin B, Lenglet T, Dubourg O, Mesnage V, Levy R. Dropped head syndrome as a presenting sign of scleromyositis. J Neurol Sci. 2010;292(1-2):101-3.
13. Rojana-Udomsart A, Fabian V, Hollingsworth PN, Walters SE, Zilko PJ, Mastaglia FL. Paraspinal and scapular myopathy associated with scleroderma. J Clin Neuromuscul Dis. 2010;11(4):213-22.
14. Ranque B, Berezne A, Le-Guern V, et al. Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features. Scand J Rheumatol. 2010;39(6):498-505.
15. Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR scleroderma trial and research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis. 2010;69(1):218-21.
16. Ringel RA, Brick JE, Brick JF, Gutmann L, Riggs JE. Muscle involvement in the scleroderma syndromes. Arch Intern Med. 1990;150(12):2550-2.
17. Ranque B, Authier FJ, Le-Guern V, et al. A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis. 2009;68(9):1474-7.
18. Scarpelli M, Montironi R, Tulli D, et al. Quantitative analysis of quadriceps muscle biopsy in systemic sclerosis. Pathol Res Pract. 1992;188(4-5):603-6.
19. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984;16(2):193-208.
20. Wolfe JF, Adelstein E, Sharp GC. Antinuclear antibody with distinct specificity for polymyositis. J Clin Invest. 1977;59(1):176-8.
21. Treadwell EL, Alspaugh MA, Wolfe JF, Sharp GC. Clinical relevance of PM-1 antibody and physiochemical characterization of PM-1 antigen. J Rheumatol. 1984;11(5):658-62.
22. Reichlin M, Maddison PJ, Targoff I, et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol. 1984;4(1):40-4.
23. Alderuccio F, Chan EK, Tan EM. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome:a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex. J Exp Med. 1991;173(4):941-52.
24. Bluthner M, Bautz FA. Cloning and characterization of the cDNA coding for a polymyositis-scleroderma overlap syndrome-related nucleolar 100-kD protein. J Exp Med. 1992;176(4):973-80.
25. Ge Q, Frank MB, O'Brien C, Targoff IN. Cloning of a complementary DNA coding for the 100-kD antigenic protein of the PM-Scl autoantigen. J Clin Invest. 1992;90(2):559-70.
26. Schilders G, van Dijk E, Raijmakers R, Pruijn GJ. Cell and molecular biology of the exosome: how to make or break an RNA. Int Rev Cytol. 2006;251:159-208.
27. Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev. 2007;6(7):432-7.
28. Reimer G, Scheer U, Peters JM, Tan EM. Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes. J Immunol. 1986;137(12):3802-8.
29. Genth E, Mierau R, Genetzky P, et al. Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum. 1990;33(5):657-65.
30. Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger Jr TA. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum. 1992;35(10):1211-7.
31. Marguerie C, Bunn CC, Copier J, et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore). 1992;71(6):327-36.
32. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al. Clinical, serologic, and immunogenetic features in polish patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40(7):1257-66.
33. Vandergheynst F, Ocmant A, Sordet C, et al. Anti-pm/scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients. Clin Exp Rheumatol. 2006;24(2):129-33.
34. Selva-O'Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar CP, Martinez-Gomez X, Vilardell-Tarres M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum. 2006;55(5):791-8.
35. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35(1):35-42.
36. Chinoy H, Salway F, Fertig N, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther. 2006;8(1):R13.
37. O'Hanlon TP, Carrick DM, Targoff IN, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A,-B,-Cw,-DRB1, and-DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore). 2006;85(2):111-27.
38. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum. 1994;37(1):75-83.
39. Hanke K, Bruckner CS, Dahnrich C, et al. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther. 2009;11(1):R22.
40. Schilders G, Egberts WV, Raijmakers R, Pruijn GJ. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome. Arthritis Rheum. 2007;56(7):2449-54.
41. Rozman B, Cucnik S, Sodin-Semrl S, et al. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis:a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis. 2008;67(9):1282-6.
42. Aggarwal R, Lebiedz-Odrobina D, Sinha A, Manadan A, Case JP. Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies. J Rheumatol. 2009;36(12):2711-4.